Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

Autor: Qinglu Cheng, Evan B. Cunningham, Sophy Shih, Janaki Amin, Julie Bruneau, Adelina A. Artenie, Jeff Powis, Alain H. Litwin, Curtis Cooper, Olav Dalgard, Margaret Hellard, Philip Bruggmann, Philippa Marks, Karine Lacombe, Catherine Stedman, Phillip Read, Behzad Hajarizadeh, Adrian J. Dunlop, Brian Conway, Jordan J. Feld, Gregory J. Dore, Jason Grebely, Gregory Dore, Sione Crawford, Tracy Swan, Jude Byrne, Melanie Lacalamita. Coordinating Centre—Amanda Erratt, Evan Cunningham, Pip Marks, Ineke Shaw, Sharmila Siriragavan, Sophie Quiene, Kathy Petoumenos, Patrick Schmid, Erika Castro, Alberto Moriggia, Jean-Pierre Daulouede, Christopher Fraser, Jordan Feld, Ed Gane, Gail Matthews, Adrian Dunlop, Ian Kronborg, David Shaw, Alain Litwin, Brianna Norton, Maria Christine Thurnheer, Martin Weltman, Philip Read, John Dillon, Simone Kessler, Cornelia Knapp, Lorenza Oprandi, Paola Messina, Marzia Pantic, Manuela Le Cam, Cecilia Maitre, Jessica Andreassen, Ingunn Melkeraaen, Merete Moen Tollefsen, Hannah Pagarigan, Rozalyn Milne, Kate Mason, Diana Kaznowski, Lily Zou, Rachel Bouchard, Barbara Kotsoros, Miriam Muir, Jessica Milloy, Victoria Oliver, Tracy Noonan, Alison Sevehon, Susan Hazelwood, Michelle Hall, Michelle Hagenauer, Rachel Liddle, Catherine Ferguson, Linda Agyemang, Hiral Patel, Irene Soloway, Orlando Cerocchi, Melanie Lacalamita, Vincenzo Fragomeli, Rosie Gilliver, Rebecca Lothian, Shirley Cleary, Linda Johnston, Sarah Middleton, Ronald D’Amico, Barbara McGovern, Jonathan Anderson, Ze Zhong, Fiona Keane, Fernando Tatsch, Diana Brainard, John McHutchison

Publikováno v: Value in Health. 26:883-892

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ee5950dc9b00953ac5284758ffc480d
https://doi.org/10.1016/j.jval.2022.12.016

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Autor: Hans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, Helmut Albrecht, Paul E Sax, Franco Maggiolo, Catherine Creticos, Claudia T Martorell, Xuelian Wei, Rima Acosta, Sean E Collins, Diana Brainard, Hal Martin

Publikováno v: The Lancet HIV. 6:e364-e372

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4d3b3c853393036c31ed5a2fe67110c
https://doi.org/10.1016/s2352-3018(19)30080-3

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

Autor: Christopher G. Fawsitt, Peter Vickerman, Graham S. Cooke, Nicky J. Welton, Eleanor Barnes, Jonathan Ball, Diana Brainard, Gary Burgess, John Dillon, Graham Foster, Charles Gore, Neil Guha, Rachel Halford, Kevin Whitby, Chris Holmes, Anita Howe, Emma Hudson, Sharon Hutchinson, William Irving, Salim Khakoo, Paul Klenerman, Natasha Martin, Benedetta Massetto, Tamyo Mbisa, John McHutchison, Jane McKeating, John McLauchlan, Alec Miners, Andrea Murray, Peter Shaw, Peter Simmonds, Chris Spencer, Emma Thomson, Nicole Zitzmann

Publikováno v: Fawsitt, C G, Vickerman, P, Cooke, G S & Welton, N J 2020, ' Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus ', Value in Health, vol. 23, no. 2, pp. 180-190 . https://doi.org/10.1016/j.jval.2019.08.012
Value in Health

Objectives Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in ∼95% of patients with hepatitis C virus. Nevertheless, patients resistant to NS5A inhibitors have lower cure

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c75b841cd2d913392eb0a841339c92b7
https://research-information.bris.ac.uk/en/publications/d4089c71-044d-413d-a696-78cab971d9ab

Development of sofosbuvir for the treatment of hepatitis C virus infection

Autor: Eric, Lawitz, Ira M, Jacobson, David R, Nelson, Stefan, Zeuzem, Mark S, Sulkowski, Rafael, Esteban, Diana, Brainard, John, McNally, William T, Symonds, John G, McHutchison, Douglas, Dieterich, Edward, Gane

Publikováno v: Annals of the New York Academy of Sciences. 1358

The nucleotide analog NS5B polymerase inhibitor sofosbuvir was approved by the U.S. Food and Drug Administration (FDA) in December 2013 for the treatment of chronic hepatitis C virus (HCV) infection in combination with ribavirin or peginterferon and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7a053661dd62a0baa71f9376949212d2
https://pubmed.ncbi.nlm.nih.gov/26235748

Premixed buffered lidocaine retains efficacy after prolonged room temperature storage

Autor: James Li, Diana Brainard

Publikováno v: The American Journal of Emergency Medicine. 18:235-236

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a23de877bfed2c3fc51181fa842b2e57
https://doi.org/10.1016/s0735-6757(00)90034-2